Champions Oncology
CSBR
17 hedge funds and large institutions have $15.3M invested in Champions Oncology in 2017 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 3 increasing their positions, 3 reducing their positions, and 2 closing their positions.
100% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 2
43% more capital invested
Capital invested by funds: $10.7M → $15.3M (+$4.61M)
13% more funds holding
Funds holding: 15 → 17 (+2)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more ownership
Funds ownership: 38% → 38.01% (+0%)
0% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$104K |
| 2 |
Millennium Management
New York
|
+$67.4K |
| 3 |
PA
Perceptive Advisors
New York
|
+$59.9K |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$55.7K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$40K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$184K |
| 2 |
SIM
Spark Investment Management
New York
|
-$53.9K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$14K |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
-$13.6K |
| 5 |
Commonwealth Equity Services
Waltham,
Massachusetts
|
-$11.3K |
CSBR Hedge Fund Activity: Q3 2017 in Review
17 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Champions Oncology (CSBR) for Q3 2017, worth a combined $15.3M — up 43% from $10.7M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new CSBR positions and 2 closed out — a net gain of 2 holders — while 3 added to existing stakes and 3 trimmed.
The largest buyer was Renaissance Technologies, adding an estimated $104K. The largest seller was Sabby Management, exiting entirely with an estimated $184K sold.
- 17 institutional investors held Champions Oncology (CSBR) as of Q3 2017, up from 15 in Q2 2017.
- Funds reported $15.3M of Champions Oncology stock for Q3 2017, up 43% quarter-over-quarter.
- 4 funds opened new Champions Oncology positions in Q3 2017 and 2 closed out, a net change of +2 holders.
- The largest Champions Oncology buyer in Q3 2017 was Renaissance Technologies, an estimated $104K added.
- The largest Champions Oncology seller in Q3 2017 was Sabby Management, an estimated $184K sold.
Based on aggregated 13F filings for Q3 2017.